COSMIC dissemination

COSMIC dissemination strategy addresses different target groups (scientists, medical doctors, industry, patient groups, students, citizens) for different purposes (e.g., raise awareness among medical doctors about systems medicine; promote research results during conferences; engage and inform patients; commercialisation) using methods tuned towards the target group and purpose (e.g., conference presentations, electronic media, science cafes, patent applications). In this context we will communicate the added value of integration of sectors for scientific excellence, for the competitiveness of companies, and for new venues for prevention, diagnostics, and treatment of B-cell lymphoma (BCL) and rheumatoid arthritis (RA).

 

COSMIC Dissemination

Figure: overview of COSMIC dissemination

 

Science-portal

For outreach and dissemination the COSMIC website (www.cosmic-h2020.eu) will provide an up-to-date resource with information for the scientific community about the consortium, research results, publications, training events, announcements, etc. The consortium will bring results and activities to the attention of a broad scientific audience by advertising the site through multiple (electronic) channels (e.g., EASyM, ISBE, EraCoSysMed, ICSB, BioSB, ELIXIR)

 SciencePortal

 

Social media

COSMIC uses Facebook, Twitter, and LinkedIn to disseminate results from the consortium and to announce (training) events.

 SocialMedia

 

Scientific newsletter

A bi-annual electronic newsletter with research, training and dissemination activities and results will be distributed among COSMIC participants and their networks.

 

Translation to clinic

Research fellows will be trained in many aspects of translational medicine and, importantly, COSMIC leverages several approaches that initiate and contribute to the translation of basic research results to clinical practice:

  • Redoxis will develop new preclinical mouse RA models to test and prioritise drugs in the preclinical phase;
  • Vivia Biotech will be involved in drug screen and development of assays for BCL;
  • We agreed with the European Advanced Translational Research Infrastructure in Medicine (EATRIS) that in case COSMIC identifies potential biomarkers or drug targets, EATRIS may be involved to evaluate the translational potential including protection of IPR, further validation, and regulatory aspects maximising possibilities for clinical implementation;
  • Anaxomics and IBM develop computational services that may be required as part of diagnostic assays,
  • Principal investigators use their network (e.g., IMI projects, H2020 health projects) to identify possibilities for follow-up.
  • Computational modelling help to identify biomarkers/targetsin silicosuitable for perturbation in vivo.

Although a clear translation element is sought for, admittedly, the full validation and development into approved assays or drug(s), and implementation in the clinic is beyond the scope and possibilities of this project given the available resources and duration.

 

COSMIC builds on recent research from the principal investigators. For example:

  • Recent research from Dr. Niek de Vries (AMC) showed that the presence of dominant BCR clones predicts short-term onset of RA in at-risk patients. Further phenotypic and molecular characterization is likely to identify novel RA biomarkers and drug targets.
  • Dr Kostas Stamotopoulos (CERTH) and Dr. Jeroen Guikema (AMC) recently identified several stereotypic B-cell receptor subgroups in various BCL subsets, providing a novel type of patient classification that improves prognostication, and yielding important insight into disease etiology. We expect that molecular characterization of the aberrant lymphocytes will identify specific disease-associated biomarkers or biological networks that discriminate between patient subgroups. Prospective novel diagnostic parameters will be validated retrospectively in selected sets of pathology specimens from BCL patients that are available to us through the AMC pathology department. Moreover, our close collaboration with Prof. Marie Joes Kersten, who heads the clinical haematology department and the clinical trial unit at the AMC, enables the assessment of the prognostic value of newly identified parameters, as she participates in several national and international clinical studies for several subsets of BCL patients.

 TranslationalMedicine

 

Dissemination to industry

The principal investigators are committed to gain further interest from industrial and SME parties, within and beyond their network, for exploitation of results (e.g., novel laboratory approaches, computational models, biomarkers, drug targets). Research fellows will be encouraged and supported by company partners and support offices to transfer research into novel IPR, commercial technologies, and ultimately, new enterprises. To keep project results close to the market, Redoxis, Anaxomics and IBM publish commercial papers business oriented journals to disseminate the main progress of COSMIC among the bioscience business professionals. The project results will be also disseminated in commercial fairs like BioEurope that Anaxomics and Redoxis regularly attend. 

 

Open Science: dissemination to scientific community

  • All partners are committed to Open Access and make COSMIC experimental data freely available through one of the public databases following FAIR (Findable, Accessible, Interoperable, Reproducible) principles.
  • Research fellows will be strongly guided and encouraged to publish in leading Open Access journals.
  • PhD theses will also be Open Access.
  • Research fellows will be stimulated to present their research at international conferences with a poster and oral presentations.
  • Academic partners are committed to Open Source and accordingly make all computational models and documentation produced in the context of COSMIC freely available through public software repositories.
  • To stimulate systems medicine training throughout Europe and beyond, all partners commit to Open Education and make all education material available through the COSMIC science portal, GOBLET training portal, and/or similar websites.

 OpenScience

 

Scientific publication in JoVE

Journal of Visualized Experiments; www.jove.com).World's only peer reviewed scientific video journal. For example, Dr. Guikema (AMC) recently published in this journal (here)  

 Jove

 

Exploitation of results and intellectual property

Results will be screened for IPR, exploitation potential, and commercialisation opportunities prior to publication. If such opportunities arise, specific arrangements (regarding revenues) will be made between the involved principal investigators (and Partner Organisations).

 


 

© 2017 COSMIC. All Rights Reserved.

Please publish modules in offcanvas position.